Geographic atrophy (GA) is an advanced stage of age-related macular degeneration (AMD) that ultimately leads to irreversible loss of vision. The incidence and prevalence of GA is expected to increase in line with an aging population. Until recently, no treatment options to effectively slow the progression of GA have been available.
An expert group of retina specialists was assembled to discuss the diagnosis and management of dry AMD and GA in the clinical setting both prior to and after the availability of a new treatment option for this disease – complement inhibition therapy.
The expert consensus group, comprising Prof Peter Kaiser, Prof Frank Holz, Prof Adnan Tufail, Prof Patricia Udaondo, Prof Stela Vujosevic and guided by Program Director Prof Anat Loewenstein attended video-conference interviews and completed a pre-interview survey to help assess agreement on the key issues discussed.
